Table 3.

Mean exploration times (±SEM) in the sample and test phases of the object-in-place task after scopolamine or mecamylamine infusions

Infusate	Timing of infusion	Condition	Exploration in sample phase (s)	Exploration in test phase (s)
				Novel	Familiar	Total
Scopolamine	Before sample phase	Vehicle	92.7 ± 2.7	21.3 ± 2.1	9.1 ± 1.0	30.5 ± 2.1
		Scopolamine	92.5 ± 3.7	17.7 ± 1.5	20.3 ± 2.7	38.1 ± 3.6
	Before test phase	Vehicle	86.8 ± 4.4	29.2 ± 3.1	11.1 ± 1.2	40.3 ± 3.2
		Scopolamine	78.6 ± 2.2	25.2 ± 2.0	11.2 ± 1.7	36.5 ± 3.1
Mecamylamine	Before sample phase	Vehicle	80.5 ± 4.1	19.6 ± 2.5	7.4 ± 0.8	27.0 ± 2.4
		Mecamylamine	79.6 ± 5.6	14.9 ± 1.8	17.9 ± 1.5	32.8 ± 2.8
	Before test phase	Vehicle	84.3 ± 2.3	22.6 ± 2.7	8.6 ± 0.5	31.3 ± 2.8
		Mecamylamine	79.8 ± 4.5	23.4 ± 2.0	10.7 ± 2.1	34.1 ± 3.7

Exploration in the test phase is presented as mean time spent exploring the novel and familiar objects separately and as total exploration.